UniProtKB/Swiss-Prot Q13421: Variant p.Met601Val

Mesothelin
Gene: MSLN
Feedback?

Variant information Variant position:

601 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Methionine (M) to Valine (V) at position 601 (M601V, p.Met601Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs1135210 [ dbSNP | Ensembl ]

Sequence information Variant position:

601 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

630 The length of the canonical sequence.
Location on the sequence:

TLGLGLQGGIPNGYLVLDLS M QEALSGTPCLLGPGPVLTVL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         TLGLGLQGGIPNGYLVLDLSMQEALSGTPCLLGPGPVLT-VL

Mouse                         RLGLGLQGGIPNGYLVLDFNVREAFSSRASLLGPGFVLIWI

Rat                           SLGLGLQGGIPNGYLILDFNVREAFSSGAPLLGPGFVFAWI

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	37 – 606	Mesothelin
Chain	296 – 606	Mesothelin, cleaved form
Lipidation	606 – 606	GPI-anchor amidated serine
Alternative sequence	601 – 630	MQEALSGTPCLLGPGPVLTVLALLLASTLA -> VQGGRGGQARAGGRAGGVEVGALSHPSLCRGPLGDALPPRTWTCSHRPGTAPSLHPGLRAPLPC. In isoform 3.

Literature citations
Molecular cloning and expression of megakaryocyte potentiating factor cDNA.
Kojima T.; Oh-Eda M.; Hattori K.; Taniguchi Y.; Tamura M.; Ochi N.; Yamaguchi N.;
J. Biol. Chem. 270:21984-21990(1995)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2); PROTEIN SEQUENCE OF 37-54 AND 90-117; TISSUE SPECIFICITY; VARIANT VAL-601; Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
Chang K.; Pastan I.;
Proc. Natl. Acad. Sci. U.S.A. 93:136-140(1996)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); SUBCELLULAR LOCATION; GPI-ANCHOR; GLYCOSYLATION; CLEAVAGE; VARIANT VAL-601; Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
Ho M.; Hassan R.; Zhang J.; Wang Q.-C.; Onda M.; Bera T.; Pastan I.;
Clin. Cancer Res. 11:3814-3820(2005)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2); DISEASE; VARIANT VAL-601; The sequence and analysis of duplication-rich human chromosome 16.
Martin J.; Han C.; Gordon L.A.; Terry A.; Prabhakar S.; She X.; Xie G.; Hellsten U.; Chan Y.M.; Altherr M.; Couronne O.; Aerts A.; Bajorek E.; Black S.; Blumer H.; Branscomb E.; Brown N.C.; Bruno W.J.; Buckingham J.M.; Callen D.F.; Campbell C.S.; Campbell M.L.; Campbell E.W.; Caoile C.; Challacombe J.F.; Chasteen L.A.; Chertkov O.; Chi H.C.; Christensen M.; Clark L.M.; Cohn J.D.; Denys M.; Detter J.C.; Dickson M.; Dimitrijevic-Bussod M.; Escobar J.; Fawcett J.J.; Flowers D.; Fotopulos D.; Glavina T.; Gomez M.; Gonzales E.; Goodstein D.; Goodwin L.A.; Grady D.L.; Grigoriev I.; Groza M.; Hammon N.; Hawkins T.; Haydu L.; Hildebrand C.E.; Huang W.; Israni S.; Jett J.; Jewett P.B.; Kadner K.; Kimball H.; Kobayashi A.; Krawczyk M.-C.; Leyba T.; Longmire J.L.; Lopez F.; Lou Y.; Lowry S.; Ludeman T.; Manohar C.F.; Mark G.A.; McMurray K.L.; Meincke L.J.; Morgan J.; Moyzis R.K.; Mundt M.O.; Munk A.C.; Nandkeshwar R.D.; Pitluck S.; Pollard M.; Predki P.; Parson-Quintana B.; Ramirez L.; Rash S.; Retterer J.; Ricke D.O.; Robinson D.L.; Rodriguez A.; Salamov A.; Saunders E.H.; Scott D.; Shough T.; Stallings R.L.; Stalvey M.; Sutherland R.D.; Tapia R.; Tesmer J.G.; Thayer N.; Thompson L.S.; Tice H.; Torney D.C.; Tran-Gyamfi M.; Tsai M.; Ulanovsky L.E.; Ustaszewska A.; Vo N.; White P.S.; Williams A.L.; Wills P.L.; Wu J.-R.; Wu K.; Yang J.; DeJong P.; Bruce D.; Doggett N.A.; Deaven L.; Schmutz J.; Grimwood J.; Richardson P.; Rokhsar D.S.; Eichler E.E.; Gilna P.; Lucas S.M.; Myers R.M.; Rubin E.M.; Pennacchio L.A.;
Nature 432:988-994(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANT VAL-601; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4); VARIANTS PRO-309 AND VAL-601; Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.
Scholler N.; Fu N.; Yang Y.; Ye Z.; Goodman G.E.; Hellstroem K.E.; Hellstroem I.;
Proc. Natl. Acad. Sci. U.S.A. 96:11531-11536(1999)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 297-630 (ISOFORM 3); PROTEIN SEQUENCE OF 296-314; VARIANT VAL-601;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.